Onconova Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.99 Insider Own0.10% Shs Outstand20.94M Perf Week0.93%
Market Cap21.90M Forward P/E- EPS next Y-0.88 Insider Trans53.48% Shs Float20.78M Perf Month-24.57%
Income-16.20M PEG- EPS next Q-0.19 Inst Own15.70% Short Float0.34% Perf Quarter-32.72%
Sales0.20M P/S109.49 EPS this Y55.70% Inst Trans-1.65% Short Ratio0.53 Perf Half Y-65.29%
Book/sh2.20 P/B0.50 EPS next Y2.70% ROA-36.10% Target Price10.00 Perf Year-88.19%
Cash/sh2.74 P/C0.40 EPS next 5Y- ROE-45.40% 52W Range1.00 - 13.80 Perf YTD-57.25%
Dividend- P/FCF- EPS past 5Y75.10% ROI-35.80% 52W High-92.10% Beta1.86
Dividend %- Quick Ratio9.10 Sales past 5Y-47.30% Gross Margin- 52W Low9.00% ATR0.09
Employees14 Current Ratio9.10 Sales Q/Q0.00% Oper. Margin- RSI (14)31.60 Volatility6.58% 7.01%
OptionableYes Debt/Eq0.00 EPS Q/Q65.50% Profit Margin- Rel Volume0.60 Prev Close1.12
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume132.84K Price1.09
Recom2.00 SMA20-14.07% SMA50-29.34% SMA200-61.50% Volume79,160 Change-2.55%
Mar-01-22Initiated Ladenburg Thalmann Buy $7
May-18-21Initiated Guggenheim Buy $4
Mar-01-18Reiterated H.C. Wainwright Buy $6 → $7.50
Jan-17-18Downgrade Maxim Group Buy → Hold
Oct-09-17Initiated H.C. Wainwright Buy $6
Apr-27-17Initiated Laidlaw Buy $10
Jul-01-15Upgrade Piper Jaffray Neutral → Overweight
May-05-15Initiated H.C. Wainwright Buy $6
May-15-22 08:04AM  
May-12-22 10:20AM  
May-11-22 04:05PM  
May-10-22 05:55PM  
May-09-22 06:45PM  
May-05-22 07:15PM  
May-04-22 04:05PM  
May-03-22 01:00PM  
Apr-27-22 10:17AM  
Mar-31-22 09:51AM  
Mar-23-22 08:00AM  
Mar-17-22 04:05PM  
Mar-10-22 04:05PM  
Feb-02-22 08:00AM  
Jan-04-22 08:00AM  
Dec-13-21 08:00AM  
Dec-06-21 08:35AM  
Dec-02-21 08:00AM  
Nov-22-21 08:00AM  
Nov-11-21 04:01PM  
Nov-04-21 03:01PM  
Oct-01-21 12:35PM  
Sep-29-21 08:00AM  
Sep-28-21 04:05PM  
Sep-24-21 12:13PM  
Sep-23-21 04:01PM  
Sep-22-21 03:15PM  
Sep-20-21 08:00AM  
Sep-09-21 08:00AM  
Aug-12-21 07:25PM  
Aug-05-21 08:00AM  
Aug-04-21 03:00PM  
Jun-28-21 08:00AM  
Jun-22-21 08:00AM  
Jun-17-21 08:00AM  
Jun-10-21 08:00AM  
Jun-04-21 12:00PM  
Jun-03-21 08:00AM  
Jun-01-21 08:00AM  
May-21-21 08:00AM  
May-20-21 08:32AM  
May-17-21 04:05PM  
May-14-21 10:25AM  
May-10-21 08:00AM  
May-06-21 03:01PM  
Apr-22-21 08:00AM  
Apr-01-21 08:00AM  
Mar-29-21 08:00AM  
Mar-11-21 04:05PM  
Mar-04-21 04:15PM  
Mar-01-21 08:00AM  
Feb-24-21 08:00AM  
Feb-22-21 09:47AM  
Feb-17-21 05:51PM  
Feb-16-21 04:03PM  
Feb-10-21 10:49PM  
Feb-04-21 11:54AM  
Jan-25-21 09:49AM  
Jan-14-21 08:00AM  
Jan-07-21 09:40AM  
Dec-21-20 08:00AM  
Dec-01-20 10:27AM  
Nov-23-20 08:00AM  
Nov-12-20 04:05PM  
Nov-05-20 08:00AM  
Oct-13-20 08:00AM  
Oct-05-20 09:44AM  
Sep-21-20 10:08AM  
Sep-09-20 08:00AM  
Aug-31-20 08:41AM  
Aug-26-20 06:42PM  
Aug-25-20 10:06AM  
Aug-24-20 11:15AM  
Aug-17-20 11:46AM  
Aug-12-20 04:37PM  
Aug-07-20 08:00AM  
Aug-04-20 08:00AM  
Aug-03-20 11:52AM  
Jul-29-20 01:30PM  
Jul-27-20 08:00AM  
Jul-23-20 08:00AM  
Jul-07-20 08:00AM  
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OLER ABRAHAM N.SVP Corp Dev & Gen CounselJan 28Buy1.671,5002,50524,514Jan 31 08:41 AM
OLER ABRAHAM N.SVP Corp Dev & Gen CounselJan 21Buy2.021,5003,03023,014Jan 24 08:40 AM
OLER ABRAHAM N.SVP CORP DEV & GEN COUNSELJan 14Buy2.201,5003,30021,514Jan 18 09:12 AM
OLER ABRAHAM N.SVP Corp Dev & Gen CounselJan 07Buy2.391,5003,58520,014Jan 10 08:39 AM
OLER ABRAHAM N.SVP CORP DEV & GEN COUNSELNov 19Buy3.161,0003,16018,514Nov 23 09:20 AM
OLER ABRAHAM N.SVP Corp Dev & Gen CounselSep 28Buy4.202,38110,00012,515Sep 29 08:27 AM
Gelder Mark S. MDChief Medical OfficerSep 28Buy4.202,38110,0002,381Sep 29 08:25 AM
Fruchtman Steven MPresident, Chief Executive OffSep 28Buy4.202,38110,00018,130Sep 28 12:34 PM
MARINO JAMES JDirectorSep 28Buy4.205,95224,99821,334Sep 28 12:32 PM